Through the collaboration, the organizations will establish a network of clinical laboratories to identify genetic mutations associated with different tumor types.
“Our arrangement with GSK will enable us to leverage our clinical, technical and quality management expertise to credential laboratory partners worldwide,” said Cindy Collins, CEO of Clarient.
The laboratory testing will initially focus on more than 70 mutations relevant to melanoma, and as the network of clinical laboratories develops, the organizations aim to expand testing beyond melanoma.
More articles on GE Healthcare:
GE Healthcare announces FDA approval of SenoClaire
5 things to know about the global HIE market
20 healthcare CEOs take on the #IceBucketChallenge
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
